<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROCHIEVE- progesterone gel </strong><br>Columbia Laboratories<br></p></div>
<h1>Prochieve<span class="Sup">®</span> 4%<br>Prochieve<span class="Sup">®</span> 8%<br>(progesterone gel)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Prochieve<span class="Sup">®</span> (progesterone gel) is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system, which is contained in single use, one piece polyethylene vaginal applicators. The carrier vehicle is an oil in water emulsion containing the water swellable, but insoluble polymer, polycarbophil. The progesterone is partially soluble in both the oil and water phase of the vehicle, with the majority of the progesterone existing as a suspension. Physically, Prochieve<span class="Sup">®</span> has the appearance of a soft, white to off-white gel.</p>
<p>The active ingredient, progesterone, is present in either a 4% or an 8% concentration (w/w). The chemical name for progesterone is pregn-4-ene-3,20-dione. It has an empirical formula of C<span class="Sub">21</span>H<span class="Sub">30</span>O<span class="Sub">2 </span>and a molecular weight of 314.5.</p>
<p>The structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-01.jpg"></p>
<p>Progesterone exists in two polymorphic forms. Form 1, which is the form used in Prochieve<span class="Sup">®</span>, exists as white orthorhombic prisms with a melting point of 127-131°C.</p>
<p>Each applicator delivers 1.125 grams of Prochieve<span class="Sup">®</span> gel containing either 45 mg (4% gel) or 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is essential for the development of decidual tissue, and the effect of progesterone on the differentiation of glandular epithelia and stroma has been extensively studied. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain the pregnancy. Normal or near-normal endometrial responses to oral estradiol and intramuscular progesterone have been noted in functionally agonadal women through the sixth decade of life. Progesterone administration decreases the circulatory levels of gonadotropins.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Due to the sustained release properties of Prochieve<span class="Sup">®</span>, progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours, and an elimination half-life of 5-20 minutes. Therefore, the pharmacokinetics of Prochieve<span class="Sup">®</span> are rate-limited by absorption rather than by elimination. </p>
<p>The bioavailability of progesterone in Prochieve<span class="Sup">®</span> was determined relative to progesterone administered intramuscularly. In a single dose crossover study, 20 healthy, estrogenized postmenopausal women received 45 mg or 90 mg progesterone vaginally in Prochieve<span class="Sup">®</span> 4% or Prochieve<span class="Sup">®</span> 8%, or 45 mg or 90 mg progesterone intramuscularly. The pharmacokinetic parameters (mean ± standard deviation) are shown in Table 1.</p>
<table width="100%">
<caption><span>TABLE 1 Single Dose Relative Bioavailability</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="left">PROCHIEVE® 4%</th>
<th class="Lrule" align="left">45 mg Intramuscular Progesterone</th>
<th class="Lrule" align="left">PROCHIEVE® 8%</th>
<th class="Lrule Rrule" align="left">90 mg Intramuscular Progesterone</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">C<span class="Sub">max</span> - maximum progesterone serum concentration<br>C<span class="Sub">avg 0-24</span> - average progesterone serum concentration over 24 hours<br>AUC<span class="Sub">0-96</span> - area under the drug concentration versus time curve from 0-96 hours post dose<br>T<span class="Sub">max</span> - time to maximum progesterone concentration<br>t<span class="Sub">1/2</span> - elimination half-life<br>F - relative bioavailability</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">C<span class="Sub">max </span>(ng/mL)</td>
<td class="Rrule" align="left">13.15±6.49</td>
<td class="Rrule" align="left">39.06±13.68</td>
<td class="Rrule" align="left">14.87±6.32</td>
<td class="Rrule" align="left">53.76±14.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">avg 0-24</span> (ng/mL)</td>
<td class="Rrule" align="left">6.94±4.24</td>
<td class="Rrule" align="left">22.41±4.92</td>
<td class="Rrule" align="left">6.98±3.21</td>
<td class="Rrule" align="left">28.98±8.75</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-96 </span>(ng∙hr/mL)</td>
<td class="Rrule" align="left">288.63±273.72</td>
<td class="Rrule" align="left">806.26±102.75</td>
<td class="Rrule" align="left">296.78±129.90</td>
<td class="Rrule" align="left">1378.91±176.39</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (hr)</td>
<td class="Rrule" align="left">5.6±1.84</td>
<td class="Rrule" align="left">8.2±6.43</td>
<td class="Rrule" align="left">6.8±3.3</td>
<td class="Rrule" align="left">9.2±2.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">t<span class="Sub">1/2 </span>(hr) </td>
<td class="Rrule" align="left">55.13±28.04</td>
<td class="Rrule" align="left">28.05±16.87</td>
<td class="Rrule" align="left">34.8±11.3</td>
<td class="Rrule" align="left">19.6±6.0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">F (%)</td>
<td class="Rrule" align="center" colspan="2">27.6</td>
<td class="Rrule" align="center" colspan="2">19.8</td>
</tr>
</tbody>
</table>
<p>The multiple dose pharmacokinetics of Prochieve<span class="Sup">®</span> 4% and Prochieve<span class="Sup">®</span> 8% administered every other day and Prochieve<span class="Sup">®</span> 8% administered daily or twice daily for 12 days were studied in 10 healthy, estrogenized postmenopausal women in two separate studies. Steady state was achieved within the first 24 hours after initiation of treatment. The pharmacokinetic parameters (mean ± standard deviation) after the last administration of Prochieve<span class="Sup">®</span> 4% or 8% derived from these studies are shown in Table 2.</p>
<table width="100%">
<caption><span>TABLE 2 Multiple Dose Pharmacokinetics</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="2">Assisted Reproductive Technology</th>
<th class="Lrule Rrule" align="center" colspan="2">Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="left">Daily Dosing 8%</th>
<th class="Lrule" align="left">Twice Daily Dosing  8%</th>
<th class="Lrule" align="left">Every Other Day Dosing 4%</th>
<th class="Lrule Rrule" align="left">Every Other Day Dosing 8%</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Rrule" align="left">15.97± 5.05</td>
<td class="Rrule" align="left">14.57 ± 4.49</td>
<td class="Rrule" align="left">13.21± 9.46</td>
<td class="Rrule" align="left">13.67 ± 3.58</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cavg  (ng/mL)</td>
<td class="Rrule" align="left">8.99 ± 3.53</td>
<td class="Rrule" align="left">11.6 ± 3.47</td>
<td class="Rrule" align="left">4.05 ± 2.85</td>
<td class="Rrule" align="left">6.75 ± 2.83</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">T<span class="Sub">max</span> (hr)</td>
<td class="Rrule" align="left">5.40 ± 0.97</td>
<td class="Rrule" align="left">3.55 ± 2.48</td>
<td class="Rrule" align="left">6.67 ± 3.16</td>
<td class="Rrule" align="left">7.00 ± 2.88</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-t </span>(ng∙hr/mL)</td>
<td class="Rrule" align="left">391.98 ±153.28</td>
<td class="Rrule" align="left">138.72 ± 41.58</td>
<td class="Rrule" align="left">242.15 ± 167.88</td>
<td class="Rrule" align="left">438.36 ± 223.36</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">t<span class="Sub">1/2</span> (hr)</td>
<td class="Rrule" align="left">45.00 ± 34.70</td>
<td class="Rrule" align="left">25.91 ± 6.15</td>
<td class="Rrule" align="left">49.87 ± 31.20</td>
<td class="Rrule" align="left">39.08 ± 12.88</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Progesterone is extensively bound to serum proteins (~96-99%), primarily to serum albumin and corticosteroid binding globulin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">The major urinary metabolite of oral progesterone is 5β-pregnan-3α, 20α-diol glucuronide which is present in plasma in the conjugated form only. Plasma metabolites also include 5β-pregnan-3α-ol-20-one (5β-pregnanolone) and 5α-pregnan-3α-ol-20-one (5β-pregnanolone). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Progesterone undergoes both biliary and renal elimination. Following an injection of labeled progesterone, 50-60% of the excretion of progesterone metabolites occurs via the kidney; approximately 10% occurs via the bile and feces, the second major excretory pathway. Overall recovery of labeled material accounts for 70% of an administered dose, with the remainder of the dose not characterized with respect to elimination. Only a small portion of unchanged progesterone is excreted in the bile.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clins"></a><a name="section-3"></a><p></p>
<h1>Clinical Studies</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Assisted Reproductive Technology</h2>
<p class="First">In a single-center, open-label study (COL1620-007US), 99 women (aged 28-47 years) with either partial (n=84) or premature <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">ovarian failure</span> (n=15) who were candidates to receive a donor oocyte transfer as an Assisted Reproductive Technology ("ART") procedure were randomized to receive either Prochieve® 8% twice daily (n=68) or intramuscular progesterone 100 mg daily (n=31). The study was divided into three phases (Pilot, Donor Egg and Treatment). The first phase of the study consisted of a test Pilot Cycle to ensure that the administration of transdermal estradiol and progesterone would adequately prime the endometrium to receive the donor egg. The second phase was the Donor Egg Cycle during which a fertilized oocyte was implanted. Prochieve® 8% was administered beginning the evening of Day 14 of the Pilot and Donor Egg cycles. Subjects with partial ovarian function also underwent a Pre-Pilot Cycle and a Pre-Donor Egg Cycle during which time they were administered only leuprolide acetate to suppress remaining ovarian function. The Pre-Pilot Cycle, Pilot Cycle, Pre-Donor Egg Cycle, and Donor Egg Cycle each lasted approximately 34 days. The third phase of the study consisted of a 10-week treatment period to maintain a pregnancy until placental autonomy was achieved. </p>
<p>Sixty-one women received Prochieve<span class="Sup">® </span>8% as part of the Pilot Cycle to determine their endometrial response. Of the 55 evaluable endometrial biopsies in the Prochieve<span class="Sup">®</span> 8% group performed on Day 25-27, all were histologically "in-phase", consistent with luteal phase biopsy specimens of menstruating women at comparable time intervals. Fifty-four women who received Prochieve<span class="Sup">®</span> 8% and had a histologically "in-phase" biopsy received a donor oocyte transfer. Among these 54 Prochieve<span class="Sup">®</span>-treated women, clinical pregnancies (assessed about week 10 after transfer by clinical examination, ultrasound and/or ß-hCG levels) occurred in 26 women (48%). Seventeen women (31%) delivered a total of 25 newborns, seven women (13%) had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> and two women (4%) had elective abortions.</p>
<p>In a second study (COL1620-F01), Prochieve<span class="Sup">®</span> 8% was used in luteal phase support of women with tubal or idiopathic <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> due to <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> and normal ovulatory cycles, undergoing in vitro fertilization ("IVF") procedures. All women received a GnRH analog to suppress endogenous progesterone, human menopausal gonadotropins, and human chorionic gonadotropin. In this multi-center, open-label study, 139 women (aged 22-38 years) received Prochieve<span class="Sup">®</span> 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer. Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>. (See <span class="Bold"><a href="#preg">PRECAUTIONS, subsection Pregnancy</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></h2>
<p class="First">In three parallel, open-label studies (COL1620-004US, COL1620-005US, COL1620-009US), 127 women (aged 18-44) with hypothalamic <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or premature <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">ovarian failure</span> were randomized to receive either Prochieve<span class="Sup">®</span> 4% (n=62) or Prochieve<span class="Sup">®</span> 8% (n=65). All women were treated with either conjugated estrogens 0.625 mg daily (n=100) or transdermal estradiol (delivering 50 mcg/day) twice weekly (n=27).  </p>
<p>Estrogen therapy was continuous for the entire three 28-day cycle studies. At Day 15 of the second cycle (six weeks after initiating estrogen replacement), women who demonstrated adequate response to estrogen therapy (by ultrasound) and who continued to be amenorrheic received Prochieve<span class="Sup">®</span> every other day for six doses (Day 15 through Day 25 of the cycle).  </p>
<p>In cycle 2, Prochieve<span class="Sup">®</span> 4% induced <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in 79% of women and Prochieve<span class="Sup">®</span> 8% induced <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in 77% of women. In the third cycle, estrogen was continued and Prochieve<span class="Sup">®</span> was administered every other day beginning on Day 15 for six doses. On Day 24 an endometrial biopsy was performed. In 53 women who received Prochieve<span class="Sup">®</span> 4%, biopsy results were as follows: 7% proliferative, 40% late secretory, 19% mid secretory, 13% early secretory, 7% atrophic, 6% menstrual endometrium, 6% inactive endometrium and 2% negative endometrium. In 54 women who received Prochieve<span class="Sup">® </span>8%, biopsy results were as follows: 44% late secretory, 19% mid secretory, 11% early secretory, 19% atrophic, 5% menstrual endometrium and 2% "oral contraceptive like" endometrium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Assisted Reproductive Technology</h2>
<p class="First">Prochieve® 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></h2>
<p class="First">Prochieve® 4% is indicated for the treatment of secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. Prochieve® 8% is indicated for use in women who have failed to respond to treatment with Prochieve® 4%.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Prochieve® should not be used in individuals with any of the following conditions:</p>
<ol class="Arabic">
<li>Known sensitivity to Prochieve®   (progesterone or any of the other ingredients)</li>
<li>Undiagnosed <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li>Liver dysfunction or disease</li>
<li>Known or suspected malignancy of the   breast or genital organs</li>
<li>Missed abortion</li>
<li>Active <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic   disorders, or a history of hormone-associated <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or   thromboembolic disorders</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The physician should be alert to the earliest manifestations of thrombotic disorders (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorders</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>). Should any of these occur or be suspected, the drug should be discontinued immediately. </p>
<p>Progesterone and progestins have been used to prevent <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> in women with a history of recurrent spontaneous pregnancy losses. No adequate evidence is available to show that they are effective for this purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<ol class="Arabic">
<li>The pretreatment physical examination   should include special reference to breast and pelvic organs, as well as   Papanicolaou smear.</li>
<li>In cases of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in   all cases of irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, nonfunctional causes should be   considered. In cases of undiagnosed <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, adequate diagnostic   measures should be undertaken.</li>
<li>Because progestogens may cause some   degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, conditions which might be influenced by this   factor (e.g., <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, cardiac or renal dysfunction)   require careful observation.</li>
<li>The pathologist should be advised of   progesterone therapy when relevant specimens are submitted.</li>
<li>Patients who have a history of psychic   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if the   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</li>
<li>A decrease in glucose tolerance has been   observed in a small percentage of patients on estrogen-progestin   combination drugs. The mechanism of this decrease is not known. For this   reason, diabetic patients should be carefully observed while receiving   progestin therapy.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The product should not be used concurrently with other local intravaginal therapy. If other local intravaginal therapy is to be used concurrently, there should be at least a 6-hour period before or after Prochieve<span class="Sup">®</span> administration. Small, white globules may appear as a <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> possibly due to gel accumulation, even several days after usage.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No drug interactions have been assessed with Prochieve®.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Nonclinical toxicity studies to determine the potential of Prochieve<span class="Sup">®</span> to cause carcinogenicity or mutagenicity have not been performed. The effect of Prochieve<span class="Sup">®</span> on fertility has not been evaluated in animals.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="preg"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">(See <span class="Bold"><a href="#clins">CLINICAL PHARMACOLOGY, subsection Clinical Studies</a></span>)
								</p>
<p>Prochieve<span class="Sup">®</span> 8% has been used to support embryo implantation and maintain pregnancies through its use as part of ART treatment regimens in two clinical studies (studies COL1620-007US and COL1620-F01). In the first study (COL1620-007US), 54 Prochieve<span class="Sup">®</span>-treated women had donor oocyte transfer procedures, and clinical pregnancies occurred in 26 women (48%). The outcomes of these 26 pregnancies were as follows: one woman had an elective termination of pregnancy at 19 weeks due to congenital malformations (<span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>) associated with a chromosomal abnormality; one woman pregnant with triplets had an elective termination of her pregnancy; seven women had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>; and 17 women delivered 25 apparently normal newborns.</p>
<p>In the second study (COL1620-F01), Prochieve® 8% was used in the luteal phase support of women undergoing in vitro fertilization ("IVF") procedures. In this multi-center, open-label study, 139 women received Prochieve<span class="Sup">®</span> 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer.</p>
<p>Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>. Of the 47 newborns delivered, one had a teratoma associated with a <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>; one had <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> syndrome; 44 were apparently normal and one was lost to follow-up.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">The safety and effectiveness in geriatric patients (over age 65) have not been established.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Detectable amounts of progestins have been identified in the milk of mothers receiving them. The effect of this on the nursing infant has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Assisted Reproductive Technology</h2>
<p class="First">In a study of 61 women with <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">ovarian failure</span> undergoing a donor oocyte transfer procedure receiving Prochieve<span class="Sup">®</span> 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3.</p>
<table width="60%">
<caption><span>TABLE 3 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Prochieve® 8% Twice Daily Study COL1620-007US (n=61)</span></caption>
<col align="left" valign="top" width="80%">
<col align="left" valign="top" width="20%">
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2">Body as a Whole </td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span></td>
<td class="Rrule" align="left">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span> NOS</td>
<td class="Rrule" align="left">15%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="left">8%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Central and Peripheral Nervous System</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="left">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left">13%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Gastro-Intestinal System</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="left">7%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Reproductive, Female</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast Pain</span></td>
<td class="Rrule" align="left">13%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">Moniliasis Genital</span></td>
<td class="Rrule" align="left">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal Discharge</span></td>
<td class="Rrule" align="left">7%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Skin and Appendages </td></tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">Pruritus Genital</span></td>
<td class="Rrule" align="left">5%</td>
</tr>
</tbody>
</table>
<p>In a second clinical study of 139 women using Prochieve<span class="Sup">®</span> 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in ≥5% of the women are shown in Table 4.</p>
<table width="60%">
<caption><span>TABLE 4 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Prochieve® 8% Once Daily Study COL1620-F01 (n=139)</span></caption>
<col align="left" valign="top" width="80%">
<col align="left" valign="top" width="20%">
<tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="2">Body as a Whole</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="left">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4021670" conceptname="Perineal pain">Perineal Pain Female</span></td>
<td class="Rrule" align="left">17%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Central and Peripheral Nervous System</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left">17%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Gastro-Intestinal System</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="left">27%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="left">22%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="left">5%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Musculo-Skeletal System</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="left">8%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Psychiatric</td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="left">11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span></td>
<td class="Rrule" align="left">10%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Rrule" align="left">16%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Rrule" align="left">27%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Reproductive, Female </td></tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">Breast Enlargement</span></td>
<td class="Rrule" align="left">40%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">Dyspareunia</span></td>
<td class="Rrule" align="left">6%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2">Urinary System</td></tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span></td>
<td class="Rrule" align="left">13%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></h2>
<p class="First">In three studies, 127 women with secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> received estrogen replacement therapy and Prochieve<span class="Sup">®</span> 4% or 8% every other day for six doses. Treatment emergent adverse events during estrogen and Prochieve® treatment that occurred in 5% or more of women are shown in Table 5.</p>
<table width="95%">
<caption><span>TABLE 5 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Estrogen Treatment and Prochieve® Every Other Day Studies COL1620-004US, COL1620-005US, COL1620-009US</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Estrogen + Prochieve® 4%<br>n=62</th>
<th class="Lrule Rrule" align="center">Estrogen + Prochieve® 8%<br> n=65</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3">Body as a Whole</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">6 (9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Appetite Increased</td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">5 (8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">Bloating</span></td>
<td class="Rrule" align="center">8 (13%)</td>
<td class="Rrule" align="center">8 (12%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span> NOS</td>
<td class="Rrule" align="center">12 (19%)</td>
<td class="Rrule" align="center">17 (26%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">13 (21%)</td>
<td class="Rrule" align="center">14 (22%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Central and Peripheral Nervous System</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">12 (19%)</td>
<td class="Rrule" align="center">10 (15%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Gastro-Intestinal System</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">4 (6%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Musculo-Skeletal System</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Rrule" align="center">5 (8%)</td>
<td class="Rrule" align="center">2 (3%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">5.(8%)</td>
<td class="Rrule" align="center">0 (0%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Psychiatric</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">12 (19%)</td>
<td class="Rrule" align="center">10 (15%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td class="Rrule" align="center">14 (23%)</td>
<td class="Rrule" align="center">14 (22%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep Disorder</span></td>
<td class="Rrule" align="center">11 (18%)</td>
<td class="Rrule" align="center">12 (18%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Reproductive, Female</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal Discharge</span></td>
<td class="Rrule" align="center">7 (11%)</td>
<td class="Rrule" align="center">2 (3%)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Resistance Mechanism</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Upper Respiratory        Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">3 (5%)</td>
<td class="Rrule" align="center">5 (8%)<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Skin and Appendages</td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Pruitis genital</td>
<td class="Rrule" align="center">1 (2%)</td>
<td class="Rrule" align="center">4 (6%)</td>
</tr>
</tbody>
</table>
<p>Additional adverse events reported in women at a frequency &lt;5% in Prochieve<span class="Sup">®</span> ART and secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> studies and not listed in the tables above include:</p>
<p>Autonomic Nervous System–<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">mouth dry</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span></p>
<p>Body as a Whole–abnormal <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span></p>
<p>Cardiovascular, General–<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p>Central and Peripheral Nervous System–<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p>Gastro-Intestinal–<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span></p>
<p>Metabolic and Nutritional–<span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p>Musculo-Skeletal System–<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps legs</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span></p>
<p>Neoplasm–benign <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span></p>
<p>Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> &amp; Clotting–<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span></p>
<p>Psychiatric–<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reactions</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p>Red Blood Cell–<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p>
<p>Reproductive, Female–<span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">premenstrual tension</span>, <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span></p>
<p>Resistance Mechanism–<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p>Respiratory System–<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></p>
<p>Skin and Appendages–<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p>Urinary System–<span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, micturition frequency</p>
<p>Vision Disorders–<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of overdosage with Prochieve®. In the case of overdosage, however, discontinue Prochieve<span class="Sup">®</span>, treat the patient symptomatically, and institute supportive measures. </p>
<p>As with all prescription drugs, this medicine should be kept out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Assisted Reproductive Technology</h2>
<p class="First">Prochieve<span class="Sup">®</span> 8% is administered vaginally at a dose of 90 mg once daily in women who require progesterone supplementation. Prochieve<span class="Sup">®</span> 8% is administered vaginally at a dose of 90 mg twice daily in women with partial or complete <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">ovarian failure</span> who require progesterone replacement. If pregnancy occurs, treatment may be continued until placental autonomy is achieved, up to 10-12 weeks. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></h2>
<p class="First">Prochieve<span class="Sup">®</span> 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of Prochieve<span class="Sup">®</span> 8% every other day up to a total of six doses may be instituted. </p>
<p>It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.</p>
<p>SEE Prochieve<span class="Sup">®</span> PATIENT INFORMATION SHEET - HOW TO USE Prochieve<span class="Sup">®</span>. <br>Note: The PATIENT INFORMATION SHEET contains special instructions for using the applicator at altitudes above 2500 feet in order to avoid a partial release of Prochieve<span class="Sup">®</span> before vaginal insertion.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Prochieve<span class="Sup">®</span> is available in the following strengths: </p>
<p>4% gel (45 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.</p>
<p>NDC-55056-0406-1 - 6 Single-use prefilled applicators.</p>
<p>8% gel (90 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.</p>
<p>NDC-55056-1601-6 - 6 Single-use prefilled applicators<br>NDC-55056-1601-5 - 15 Single-use prefilled applicators <br>NDC-55056-1601-8 - 18 Single-use prefilled applicators</p>
<p>Each applicator is wrapped and sealed in a foil overwrap.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Rx only.</p>
<p>U.S. Patent Number 5,543,150.</p>
<p><span class="Bold">Manufactured for: </span>Columbia Laboratories, Inc. Livingston, NJ 07039</p>
<p><span class="Bold">Manufactured by:</span> Fleet Laboratories Ltd., Watford, United Kingdom</p>
<p>Revised May 2009</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-13"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Prochieve<span class="Sup">®</span> 8%</span><br>(progesterone gel)<br>For Vaginal Use Only</p>
<p><span class="Bold">FOR PROGESTERONE SUPPLEMENTATION OR REPLACEMENT AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY ("ART") TREATMENT FOR INFERTILE WOMEN WITH PROGESTERONE DEFICIENCY</span></p>
<p>Please read this information carefully before you start to use Prochieve<span class="Sup">®</span> and each time your prescription is renewed, in case anything has changed. This leaflet does not take the place of discussions with your doctor. If you still have any questions, ask your doctor or health-care provider.</p>
<p><span class="Bold">What Prochieve<span class="Sup">®</span> is</span></p>
<p>Prochieve® is a specially formulated gel that you insert in your vagina. It contains the natural female hormone called progesterone. Prochieve<span class="Sup">®</span> 8% is used as part of a program for women who are undergoing fertility treatment.</p>
<p><span class="Bold">Understanding the role of Prochieve<span class="Sup">®</span> in your <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> treatment</span></p>
<p>Progesterone is one of the hormones essential for maintaining a pregnancy. If you are undergoing ART treatment and your doctor has determined your body does not produce enough progesterone on its own, Prochieve<span class="Sup">®</span> may be prescribed to provide the progesterone you need. </p>
<p>The progesterone in Prochieve® will help prepare the lining of your uterus so that it is ready to receive and nourish a fertilized egg. If pregnancy occurs, Prochieve<span class="Sup">®</span> may be supplemented for 10-12 weeks until production of progesterone by the placenta is adequate.</p>
<p><span class="Bold">When you should not use Prochieve<span class="Sup">®</span></span></p>
<ul class="Disc">
<li>If you are allergic to progesterone,   progesterone-like drugs, or any of the inactive ingredients in the gel   (ask a pharmacist if you are not sure about the inactive ingredients in   Prochieve<span class="Sup">®)</span>.</li>
<li>If you have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>   which has not been evaluated by a doctor.</li>
<li>If you have a liver disease.</li>
<li>If you have known or suspected cancer of   the breast or genital organs.</li>
<li>If you have a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and your   physician suspects some tissue is still in the uterus.</li>
<li>If you have or have had blood clots in   the legs, lungs, eyes, or elsewhere.</li>
</ul>
<p><span class="Bold">Risks of Prochieve<span class="Sup">®</span></span></p>
<ul class="Disc">
<li>Risk to the fetus. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> have   been reported in the offspring of women who were using Prochieve® during   early pregnancy. These included an abdominal wall defect and a cleft   palate. A causal association has been neither confirmed nor refuted. You   should check with your doctor about the risks to your unborn child of any   medication used during pregnancy.</li>
<li>Blood clots and related health problems.   Blood clots have been reported with the use of estrogens and   progestational drugs (alone or in combination). If blood clots do form in   your bloodstream, they can cut off the blood supply to vital organs,   causing serious problems. These problems may include a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (by cutting   off blood to part of the brain), a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> (by cutting off blood to   part of the heart), a <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> (by cutting off blood to part of   the lungs), or other problems. Any of these conditions may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or   serious long-term <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Call your doctor immediately if you suspect   you have any of these conditions. He or she may advise you to stop using   this drug.</li>
</ul>
<p><span class="Bold">PRECAUTIONS</span></p>
<p>Be alert for unusual signs and symptoms. If any of these warning signals (or any other unusual symptoms) happen while you are using Prochieve®, call your doctor immediately:</p>
<ul class="Disc">
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina.</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in the calves or chest, a sudden   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">coughing blood</span> indicating possible clots in the   legs, heart, or lungs.</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>,   faintness, or changes in vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of an arm   or leg indicating possible clots in the brain or eye.</li>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span>, which could be associated   with fibrocystic disorders, fibroadenoma, or breast cancer. (Ask your   doctor or health-care provider to show you how to examine your breasts   monthly.)</li>
<li>Yellowing of the skin and/or white of the   eyes indicating possible liver problems.</li>
</ul>
<p>You should also notify your doctor if you experience <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, worsening of your diabetic condition, or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<p>Possible side effects of Prochieve<span class="Sup">®</span></p>
<p>In addition to the risks listed above, the following side effects have been reported with Prochieve<span class="Sup">®</span> used either for progesterone supplementation or for replacement as part of an ART treatment for infertile women with progesterone deficiency. Consult your doctor if you experience any of the side effects mentioned below, or other side effects.</p>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY OF 5% OR GREATER</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="4021670" conceptname="Perineal pain">perineal pain</span> (the   perineum is the area between the vagina and the rectum)</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; decreased libido;   <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span></li>
<li>excessive urination at night</li>
</ul>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY RANGING FROM 1% TO 5%</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>; <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><a href="#footnote-1" class="Sup">1</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span></li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span></li>
<li>difficult or painful intercourse; genital   <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; genital <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>; <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span></li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></li>
</ul>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY OF LESS THAN 1%</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; flu-like symptoms</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span>; gas;   abdominal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>; <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; upper respiratory tract   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>painful or difficult urination; frequent   urination</li>
</ul>
<p><span class="Bold">How Prochieve<span class="Sup">®</span> works</span></p>
<p>Prochieve<span class="Sup">®</span> has been formulated to be administered through the vagina. The moisturizing gel in Prochieve® forms a coating on the walls of the vagina which allows for absorption of progesterone through the vaginal tissue. Small, white globules may appear as a <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> possibly due to gel accumulation, even several days after usage. Prochieve® contains no irritating perfumes or dyes.</p>
<p><span class="Bold">Other information</span></p>
<ol>
<li>Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else.</li>
<li>This medication was prescribed for your particular medical condition. Do not use it for another condition.</li>
<li>Keep this and all drugs out of the reach of children.</li>
</ol>
<p><span class="Bold">How to use Prochieve<span class="Sup">®</span></span></p>
<p>The dosage is one application of the 8% gel (90 mg of progesterone) vaginally, daily or twice daily as directed by your doctor. If you become pregnant, your doctor may decide to continue treatment for up to 10 to 12 weeks.</p>
<p>Prochieve<span class="Sup">®</span> is to be applied directly from the specially designed sealed applicator into the vagina. The applicator is designed to deliver a premeasured dose of Prochieve®. A small amount of gel will be left in the tube after usage. Do not be concerned because you will still be receiving the appropriate, measured dosage.</p>
<p>Under certain rare circumstances, such as high altitude, brief exposure to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span>, sudden changes in atmospheric/barometric pressure, and pressure controlled environments such as airplanes or high-rise buildings, the internal pressure of the applicator may become higher than the air pressure.  This imbalance between the internal and external pressure may cause the gel to expel from the applicator when the twist-off tab is removed.  If you should experience the gel expelling from the applicator upon opening, please follow the SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET.</p>
<dl>
<dt class="Italics">1.</dt>
<dd>Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. <span class="Italics">For use at altitudes above 2500 feet, see <a href="#SI1">special instructions</a> below.</span>
</dd>
<dt>2.</dt>
<dd>Hold the applicator between the thumb and forefinger along the seam on the sides of the bulb. Shake down vigorously 3 to 4 times (like a thermometer) to ensure that the contents are at the thin end of the applicator.
								<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-02.jpg"></div>
<br>
</dd>
<dt>3.</dt>
<dd>Hold the applicator by the flat section of the bulb. Twist off the tab at the thin end and throw away. DO NOT squeeze the bulb while twisting the tab. This could force some gel to be released before it is inserted.
								<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-03.jpg"></div>
<br>Twist off completely – Do not pull off</dd>
<dt>4.</dt>
<dd>The applicator may be inserted into the vagina while you are in a sitting position or when lying on your back with your knees bent. <span class="Underline">Gently insert the thin end well into the vagina.</span><br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-04.jpg"></div>
<br>
</dd>
<dt>5.</dt>
<dd>Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-05.jpg"></div>
<br>
</dd>
</dl>
<p><a name="SI1"></a>SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET</p>
<ol>
<li>Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. Hold the applicator on both sides of the bulb, as shown. Using a lancet or a stick pin, make a single puncture in the flat part of the bulb. This will relieve the difference in air pressure between the inside and outside of the applicator caused by high altitudes. It will not affect the amount of gel administered. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-06.jpg"></div>
<br>
</li>
<li>See Step 2 above.</li>
<li>See Step 3 above.</li>
<li>See Step 4 above.</li>
<li>Place your thumb or finger over the puncture that you made in the bulb of the applicator. Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-05.jpg"></div>
<br>
</li>
</ol>
<p>Prochieve<span class="Sup">®</span> coats the vaginal lining to provide long-lasting release of progesterone. Small, white globules may appear as a <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> possibly due to gel accumulation, even several days after usage. It is not unusual, but if you are concerned, discuss this with your doctor. </p>
<p>If you forget a dose of Prochieve<span class="Sup">®</span>, use it as soon as you remember, but do not use more than the recommended daily dose. Prochieve® should not be used at the same time that you are using other vaginal therapy. </p>
<p>This leaflet provides the most important information about Prochieve<span class="Sup">®</span>. If you want to read more, ask your doctor or pharmacist about the professional leaflet. You may need their help to understand some of the information.</p>
<p><span class="Bold">How Supplied</span></p>
<p>Prochieve<span class="Sup">®</span> is available in two strengths: 4% gel (45 mg of progesterone) and 8% gel (90 mg of progesterone).</p>
<p>Each box of the 4% gel contains six single use, disposable vaginal applicators with a twist-off tab. Each box of the 8% gel contains either six, fifteen, or eighteen single use, disposable vaginal applicators with a twist-off tab. Each applicator is wrapped and sealed in a foil overwrap. </p>
<p>Prochieve<span class="Sup">®</span> should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).</p>
<p>Do not use Prochieve<span class="Sup">®</span> after the expiration date which is printed on the box.</p>
<p><span class="Bold">Manufactured for:</span> Columbia Laboratories, Inc., Livingston, NJ 07039</p>
<p><span class="Bold">Manufactured by:</span> Fleet Laboratories Ltd., Watford, United Kingdom</p>
<p>Revised May 2009</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>If you experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, do not drive or operate machinery.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>This may worsen some conditions such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, heart disease, or kidney disease.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Prochieve<span class="Sup">®</span> 4% and Prochieve<span class="Sup">®</span> 8%</span> (progesterone gel)<br>For Vaginal Use Only</p>
<p><span class="Bold">FOR THE TREATMENT OF SECONDARY <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">AMENORRHEA</span> (ABSENCE OF MENSES IN WOMEN WHO HAVE PREVIOUSLY HAD A MENSTRUAL PERIOD)</span></p>
<p>Please read this information carefully before you start to use Prochieve<span class="Sup">®</span> and each time your prescription is renewed, in case anything has changed. This leaflet does not take the place of discussions with your doctor. If you still have any questions, ask your doctor or health-care provider.</p>
<p><span class="Bold">What Prochieve<span class="Sup">®</span> is</span></p>
<p>Prochieve<span class="Sup">®</span> is a specially formulated gel that you insert in your vagina. It contains the natural female hormone called progesterone. The 4% gel is used for women whose menstrual cycle has stopped. The 8% gel is to be used when the 4% gel has not worked.</p>
<p><span class="Bold">Understanding the role of Prochieve<span class="Sup">®</span> in the treatment of your menstrual irregularities</span></p>
<p>Progesterone is one of the hormones essential for regular menstrual periods. If your doctor has determined your body does not produce enough progesterone on its own, Prochieve<span class="Sup">®</span> may be prescribed to provide the progesterone you need. </p>
<p>When you do not produce enough progesterone, menstrual irregularities can occur. Prochieve<span class="Sup">®</span> can provide you with the progesterone needed during a normal menstrual cycle.</p>
<p><span class="Bold">When you should not use Prochieve<span class="Sup">®</span></span></p>
<ul class="Disc">
<li>If you are allergic to progesterone,   progesterone-like drugs, or any of the inactive ingredients in the gel   (ask a pharmacist if you are not sure about the inactive ingredients in   Prochieve<span class="Sup">®)</span>.</li>
<li>If you have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>   which has not been evaluated by a doctor.</li>
<li>If you have a liver disease.</li>
<li>If you have known or suspected cancer of   the breast or genital organs.</li>
<li>If you have a <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> and your   physician suspects some tissue is still in the uterus.</li>
<li>If you have or have had blood clots in   the legs, lungs, eyes, or elsewhere.</li>
</ul>
<p><span class="Bold">Risks of Prochieve<span class="Sup">®</span></span></p>
<ul class="Disc">
<li>Risk to the fetus. <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> have   been reported in the offspring of women who were using Prochieve® during   early pregnancy. These included an abdominal wall defect and a cleft   palate. A causal association has been neither confirmed nor refuted. You   should check with your doctor about the risks to your unborn child of any   medication used during pregnancy.</li>
<li>Blood clots and related health problems.   Blood clots have been reported with the use of estrogens and   progestational drugs (alone or in combination). If blood clots do form in   your bloodstream, they can cut off the blood supply to vital organs,   causing serious problems. These problems may include a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (by cutting   off blood to part of the brain), a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> (by cutting off blood to   part of the heart), a <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span> (by cutting off blood to part of   the lungs), or other problems. Any of these conditions may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or   serious long-term <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Call your doctor immediately if you suspect   you have any of these conditions. He or she may advise you to stop using   this drug.</li>
</ul>
<p><span class="Bold">PRECAUTIONS</span></p>
<p>Be alert for unusual signs and symptoms. If any of these warning signals (or any other unusual symptoms) happen while you are using Prochieve®, call your doctor immediately:</p>
<ul class="Disc">
<li>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina.</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in the calves or chest, a sudden   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">coughing blood</span> indicating possible clots in the   legs, heart, or lungs.</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>,   faintness, or changes in vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of an arm   or leg indicating possible clots in the brain or eye.</li>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span>, which could be associated   with fibrocystic disorders, fibroadenoma, or breast cancer. (Ask your   doctor or health-care provider to show you how to examine your breasts   monthly.)</li>
<li>Yellowing of the skin and/or white of the   eyes indicating possible liver problems.</li>
</ul>
<p>You should also notify your doctor if you experience <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, worsening of your diabetic condition, or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<p><span class="Bold">Possible side effects of Prochieve<span class="Sup">®</span></span></p>
<p>In addition to the risks listed above, the following side effects have been reported in studies with Prochieve<span class="Sup">®</span> used for the treatment of menstrual irregularities due to progesterone deficiency. In these studies, women were treated with estrogen prior to and during Prochieve<span class="Sup">®</span> therapy. All side effects reported at a frequency of 5% or greater after Prochieve<span class="Sup">®</span> was added to estrogen therapy also were reported with estrogen therapy alone. Consult your doctor if you experience any of the side effects mentioned below, or other side effects.</p>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY OF 5% OR GREATER</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>;   <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>; <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span></li>
<li><span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span></li>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
</ul>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY RANGING FROM 1% TO 5%</p>
<ul class="Disc">
<li>increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>; flu-like symptoms; <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>;   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li>
<li>gas; <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span></li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></li>
<li><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span><a href="#footnote-3" class="Sup">3</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>; painful menstruation</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; genital <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>; genital <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span></li>
<li>frequent urination</li>
</ul>
<p>SIDE EFFECTS REPORTED AT A FREQUENCY OF LESS THAN 1%</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li>abnormal <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>;   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>; <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>; <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="product-label-link" type="condition" conceptid="4021670" conceptname="Perineal pain">perineal pain</span> (the   perineum is the area between the vagina and the rectum); <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a>;   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>abdominal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span></li>
<li>non-cancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span></li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>; <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span></li>
<li><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="439081" conceptname="Premenstrual tension syndrome">premenstrual syndrome</span>; <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li>rapid, <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>; shortness of   breath; <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; oily or dry scaly skin;   <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span></li>
<li><span class="product-label-link" type="condition" conceptid="4128384" conceptname="Non-infective cystitis">bladder inflammation</span>; painful or   difficult urination</li>
<li>"pink eye"</li>
</ul>
<p><span class="Bold">How Prochieve<span class="Sup">®</span> works</span></p>
<p>Prochieve<span class="Sup">®</span> has been formulated to be administered through the vagina. The moisturizing gel in Prochieve<span class="Sup">®</span> forms a coating on the walls of the vagina which allows for absorption of progesterone through the vaginal tissue. Small, white globules may appear as a <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> possibly due to gel accumulation, even several days after usage. Prochieve<span class="Sup">®</span> contains no irritating perfumes or dyes.</p>
<p><span class="Bold">Other information</span></p>
<ol>
<li>Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else.</li>
<li>This medication was prescribed for your particular medical condition. Do not use it for another condition.</li>
<li>Keep this and all drugs out of the reach of children.</li>
</ol>
<p><span class="Bold">How to use Prochieve<span class="Sup">®</span></span></p>
<p>The dosage is one application of the 4% gel (45 mg of progesterone), vaginally, every other day as directed by your doctor, for a total of six doses. In some cases, your doctor may prescribe the 8% gel (90 mg of progesterone) every other day, for a total of six doses.</p>
<p>It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.</p>
<p>Prochieve<span class="Sup">®</span> is to be applied directly from the specially designed sealed applicator into the vagina. The applicator is designed to deliver a premeasured dose of Prochieve<span class="Sup">®</span>. A small amount of gel will be left in the tube after usage. Do not be concerned because you will still be receiving the appropriate, measured dosage.</p>
<p>Under certain rare circumstances, such as high altitude, brief exposure to <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span>, sudden changes in atmospheric/barometric pressure, and pressure controlled environments such as airplanes or high-rise buildings, the internal pressure of the applicator may become higher than the air pressure.  This imbalance between the internal and external pressure may cause the gel to expel from the applicator when the twist-off tab is removed.  If you should experience the gel expelling from the applicator upon opening, please follow the SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET.</p>
<dl>
<dt class="Italics">1.</dt>
<dd>Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. <span class="Italics">For use at altitudes above 2500 feet, see <a href="#SI2">special instructions</a> below.</span>
</dd>
<dt>2.</dt>
<dd>Hold the applicator between the thumb and forefinger along the seam on the sides of the bulb. Shake down vigorously 3 to 4 times (like a thermometer) to ensure that the contents are at the thin end of the applicator.
								<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-02.jpg"></div>
<br>
</dd>
<dt>3.</dt>
<dd>Hold the applicator by the flat section of the bulb. Twist off the tab at the thin end and throw away. DO NOT squeeze the bulb while twisting the tab. This could force some gel to be released before it is inserted.
								<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-03.jpg"></div>
<br>Twist off completely – Do not pull off</dd>
<dt>4.</dt>
<dd>The applicator may be inserted into the vagina while you are in a sitting position or when lying on your back with your knees bent. <span class="Underline">Gently insert the thin end well into the vagina.</span><br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-04.jpg"></div>
<br>
</dd>
<dt>5.</dt>
<dd>Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-05.jpg"></div>
<br>
</dd>
</dl>
<p><a name="SI2"></a>SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET</p>
<ol>
<li>Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. Hold the applicator on both sides of the bulb, as shown. Using a lancet or a stick pin, make a single puncture in the flat part of the bulb. This will relieve the difference in air pressure between the inside and outside of the applicator caused by high altitudes. It will not affect the amount of gel administered. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-06.jpg"></div>
<br>
</li>
<li>See Step 2 above.</li>
<li>See Step 3 above.</li>
<li>See Step 4 above.</li>
<li>Place your thumb or finger over the puncture that you made in the bulb of the applicator. Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.<br><div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-05.jpg"></div>
<br>
</li>
</ol>
<p>Prochieve<span class="Sup">®</span> coats the vaginal lining to provide long-lasting release of progesterone. Small, white globules may appear as a <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> possibly due to gel accumulation, even several days after usage. It is not unusual, but if you are concerned, discuss this with your doctor.</p>
<p>If you forget a dose of Prochieve<span class="Sup">®</span>, use it as soon as you remember, but do not use more than the recommended daily dose. Prochieve® should not be used at the same time that you are using other vaginal therapy. </p>
<p>This leaflet provides the most important information about Prochieve®. If you want to read more, ask your doctor or pharmacist about the professional leaflet. You may need their help to understand some of the information.</p>
<p><span class="Bold">How Supplied</span></p>
<p>Prochieve<span class="Sup">®</span> is available in two strengths: 4% gel (45 mg of progesterone) and 8% gel (90 mg of progesterone).</p>
<p>Each box of the 4% gel contains six single use, disposable vaginal applicators with a twist-off tab. Each box of the 8% gel contains either six, fifteen, or eighteen single use, disposable vaginal applicators with a twist-off tab. Each applicator is wrapped and sealed in a foil overwrap. </p>
<p>Prochieve<span class="Sup">®</span> should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).</p>
<p>Do not use Prochieve<span class="Sup">®</span> after the expiration date which is printed on the box.</p>
<p><span class="Bold">Manufactured for:</span> Columbia Laboratories, Inc., Livingston, NJ 07039</p>
<p><span class="Bold">Manufactured by:</span> Fleet Laboratories Ltd., Watford, United Kingdom</p>
<p>Revised May 2009</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>If you experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, do not drive or operate machinery.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>This may worsen some conditions such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, heart disease, or kidney disease.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 4% / 6 Single-Use Prefilled Applicator Carton</h1>
<p class="First"><span class="Bold">Prochieve<span class="Sup">® </span> 4%</span><br>
						(progesterone gel)</p>
<p>NDC 55056-0406-1</p>
<p>6 Single-Use Prefilled Applicators</p>
<p>Each applicator contains 1.45g of gel<br>
and delivers 1.125g of gel containing<br>
45mg progesterone.</p>
<p>FOR VAGINAL USE ONLY</p>
<p><span class="Bold">COLUMBIA<br>
LABORATORIES</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 4% / 6 Single-Use Prefilled Applicator Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 8% / 15 Single-Use Prefilled Applicator Carton</h1>
<p class="First"><span class="Bold">PROCHIEVE<span class="Sup">® </span> 8%</span><br>
						(progesterone gel)</p>
<p>NDC 55056-1601-5</p>
<p>15 Single-Use Prefilled Applicators</p>
<p>Each applicator contains 1.45 g of gel<br>
and delivers 1.125 g of gel containing<br>
90 mg progesterone.</p>
<p>FOR VAGINAL USE ONLY</p>
<p><span class="Bold">COLUMBIA<br>
LABORATORIES</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 8% / 15 Single-Use Prefilled Applicator Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9f8dc923-65d7-42ff-b718-97e7a7e87822&amp;name=prochieve-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROCHIEVE 		
					</strong><br><span class="contentTableReg">progesterone gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55056-0406</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>progesterone</strong> (progesterone) </td>
<td class="formItem">progesterone</td>
<td class="formItem">45 mg  in 1.125 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polycarbophil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carbomer 934</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrogenated palm oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55056-0406-1</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.125 g in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020701</td>
<td class="formItem">05/13/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROCHIEVE 		
					</strong><br><span class="contentTableReg">progesterone gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55056-1601</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>progesterone</strong> (progesterone) </td>
<td class="formItem">progesterone</td>
<td class="formItem">90 mg  in 1.125 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polycarbophil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carbomer 934</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrogenated palm oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE, WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55056-1601-6</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.125 g in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55056-1601-5</td>
<td class="formItem">15  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1.125 g in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55056-1601-8</td>
<td class="formItem">18  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1.125 g in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020701</td>
<td class="formItem">05/13/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Columbia Laboratories
							(177253754)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Columbia Laboratories Inc</td>
<td class="formItem"></td>
<td class="formItem">177253754</td>
<td class="formItem">REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ea8a930-2eae-435e-b13c-f2c9e9a4bf00</div>
<div>Set id: 9f8dc923-65d7-42ff-b718-97e7a7e87822</div>
<div>Version: 1</div>
<div>Effective Time: 20091119</div>
</div>
</div> <div class="DistributorName">Columbia Laboratories</div></p>
</body></html>
